Perpetua Life Announces Launch of Perpetua Life Biotech UK Ltd

Press Release: January 12, 2024

  • Share This Article
  • Facebook
  • Twitter
  • Pintrest
  • LinkedIn
  • Mail
Perpetua Life Announces Launch of Perpetua Life Biotech UK Ltd
Pioneering US Startup focused on longevity supplementation establishes Local UK presence

LONDON, UK. 12th January 2024 – In a significant stride towards global expansion, Perpetua Life Biotech, a U.S.-based startup specialising in gerontology and longevity medicine, proudly announces the establishment of Perpetua Life Biotech UK Ltd. The newly formed UK entity aims to enhance accessibility for the local market and foster collaborations with UK businesses and retailers.

Founded in 2017 by three biology post-grad students at Boston College, Perpetua Life Biotech embarked on a mission to fill a void in the life extension market. After years of dedicated research and development, the company introduced its flagship product, AEON, in 2021. Dr. Michael Morgan, CEO of Perpetua Life Biotech states: “AEON was created to be an all-in-one longevity focused supplement. Each compound chosen for its stand-alone benefits as well as its synergistic ones paired with the other 10”. 

 
Dr. Morgan explained that many exciting studies are underway using compounds like Metformin, Low dose Naltrexone, and Rapamycin (Sirolimus) which are showing promising results when it comes to extending life. 
 
When considering food supplements, compounds like Nicotinamide Mononucleotide (NMN), Nicotinamide Riboside (NR), Trans-Resveratrol, Fisetin, Astragalus, Quercetin and Spermidine are some of the most important compounds that have a combined 1,000+ published research papers outlining their anti-aging, and anti-inflammatory benefits.
 
The latest development of the establishment of Perpetua Life Biotech UK Ltd. marks a strategic move to cater directly to the UK market. Despite the US company’s ability to ship worldwide, UK customers faced challenges such as extended delivery times and high customs fees. The new UK presence solves these problems, offering a streamlined and more affordable experience for British customers. 
 
Perpetua Life Biotech UK Ltd. is already working toward expansion into the EU for localised distribution, making its products more easily available across the European mainland.
 
Dr. Michael Morgan, CEO of Perpetua Life Biotech, expressed his enthusiasm about the news, commenting, “We are excited to embark on this new chapter for Perpetua Life Biotech with the establishment of Perpetua Life Biotech UK Ltd. The UK’s reputation as a hub for innovation in the life sciences aligns perfectly with our mission to create transformative biotechnological solutions. 
 
Dr Morgan concludes: “Despite very exciting developments in the anti-aging space we should not lose track of what can be done right now to fight the aging process and the benefits of regular exercise, fasting, good quality sleep, a healthy diet and the alleviation of stress should not be underestimated in its role to fight the aging process”. 
 
Perpetua Life Biotech remains steadfast in its commitment to advancing longevity research globally, and the launch of Perpetua Life Biotech UK Ltd. underscores the company’s dedication to providing accessible and innovative solutions to support healthy aging.
 
Expect 2024 to continue to deliver encouraging news from Perpetua Life for those interested in Life Extension research and advancements, 

For more information, visit https://www.perpetualife.uk

ENDS


  • Share This Article
  • Facebook
  • Twitter
  • Pintrest
  • LinkedIn
  • Mail